Clinical Effects of Gemifloxacin on the Delay of Tuberculosis Treatment.
10.3346/jkms.2013.28.3.378
- Author:
Seo Yun KIM
1
;
Jae Joon YIM
;
Jong Sun PARK
;
Sung Soo PARK
;
Eun Young HEO
;
Chang Hoon LEE
;
Hee Soon CHUNG
;
Deog Kyeom KIM
Author Information
1. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Korea. kimdkmd@snu.ac.kr
- Publication Type:Original Article ; Controlled Clinical Trial
- Keywords:
Fluoroquinolones;
Tuberculosis;
Pneumonia
- MeSH:
Adult;
Aged;
Anti-Bacterial Agents/*therapeutic use;
Case-Control Studies;
Fluoroquinolones/*therapeutic use;
Humans;
Middle Aged;
Naphthyridines/*therapeutic use;
Pneumonia/complications/diagnosis;
Tuberculosis/complications/*drug therapy/radiography
- From:Journal of Korean Medical Science
2013;28(3):378-382
- CountryRepublic of Korea
- Language:English
-
Abstract:
Although gemifloxacin has low in vitro activity against Mycobacterium tuberculosis, the effect of gemifloxacin on the delay of tuberculosis (TB) treatment has not been validated in a clinical setting. The study group included patients with culture-confirmed pulmonary TB who initially received gemifloxacin for suspected community-acquired pneumonia (CAP). Two control groups contained patients treated with other fluoroquinolones or nonfluoroquinolone antibiotics. Sixteen cases were treated with gemifloxacin for suspected CAP before TB diagnosis. Sixteen and 32 patients were treated with other fluoroquinolones and nonfluoroquinolones, respectively. The median period from the initiation of antibiotics to the administration of anti-TB medication was nine days in the gemifloxacin group, which was significantly different from the other fluoroquinolones group (35 days). The median times for the nonfluoroquinolone group and the gemifloxacin group were not significantly different. There were no significant differences between the gemifloxacin and other fluoroquinolone group in terms of symptomatic and radiographic improvements. However, the frequency of radiographic improvement in the other fluoroquinolones group tended to be higher than in the gemifloxacin group. Gemifloxacin might be the preferred fluoroquinolone for treating CAP, to alleviate any concerns about delaying TB treatment.
